A5042459008- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Viral-associated cancers and disorders
- Mesenchymal stem cell research
- Cancer Genomics and Diagnostics
- RNA Interference and Gene Delivery
- Cancer Immunotherapy and Biomarkers
- Medical Imaging Techniques and Applications
- Virus-based gene therapy research
- Protein Degradation and Inhibitors
- Synthesis and pharmacology of benzodiazepine derivatives
- CNS Lymphoma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Hematological disorders and diagnostics
- Cell death mechanisms and regulation
Humanitas University
2016-2025
IRCCS Humanitas Research Hospital
2014-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2008-2023
Vall d'Hebron Hospital Universitari
2023
Vall d'Hebron Institute of Oncology
2023
University College London
2023
Fundación Juan March
2023
University of Oxford
2023
University College Hospital
2023
Memorial Sloan Kettering Cancer Center
2023
The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is poor. Glofitamab a bispecific antibody that recruits T cells to tumor cells.In the phase 2 part of 1-2 study, we enrolled DLBCL who had received at least two lines therapy previously. Patients pretreatment obinutuzumab mitigate cytokine release syndrome, followed by fixed-duration glofitamab monotherapy (12 cycles total). primary end point was complete response according assessment an independent...
Glofitamab is a T-cell-engaging bispecific antibody possessing novel 2:1 structure with bivalency for CD20 on B cells and monovalency CD3 T cells. This phase I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Data single-agent glofitamab, obinutuzumab pretreatment (
Abstract Group 2 innate lymphoid cells (ILC2s) are involved in human diseases, such as allergy, atopic dermatitis and nasal polyposis, but their function cancer remains unclear. Here we show that, acute promyelocytic leukaemia (APL), ILC2s increased hyper-activated through the interaction of CRTH2 NKp30 with elevated tumour-derived PGD2 B7H6, respectively. ILC2s, turn, activate monocytic myeloid-derived suppressor (M-MDSCs) via IL-13 secretion. Upon treating APL all-trans retinoic acid...
In addition to immunologic derangement, hematological abnormalities have been reported in the majority of patients with acquired immunodeficiency syndrome (AIDS). this study 15 AIDS or AIDS-related complex (ARC) were evaluated for vitro growth hemopoietic progenitor cells. all a significant reduction (mean +/- SEM) colony-forming unit-granulocyte, erythrocyte, macrophage, (megakaryocyte) (CFU-GEM) (1.2 0.3), burst-forming unit-erythroid (BFU-E) (17 10), CFU-megakaryocyte (CFU-Mk) (1.7 0.6),...
Recently, the administration of high-dose cyclophosphamide (Cy) after T cell–replete haploidentical stem cell infusion has been reported to be feasible and effective. In original study, bone marrow (BM) was used as source cells. Here, we retrospectively analyzed use BM versus peripheral blood cells (PBSCs) in a cohort patients receiving transplantation nonmyeloablative conditioning regimen with postinfusion Cy. PBSC groups, incidence acute graft-versus-host disease (GVHD) 33% 25%,...
Abstract Increasing evidence argues that the success of an anticancer treatment may rely on immunoadjuvant side effects including induction immunogenic tumor cell death. Based assumption this death mechanism is a similar prerequisite for efficacy active immunotherapy using killed cells, we examined vaccination strategy dendritic cells (DC) loaded with apoptotic and necrotic bodies derived from autologous tumors. Using approach, clinical immunologic responses were achieved in 6 18 patients...
Abstract Background Recently, a platform of T‐cell replete haploidentical hematopoietic stem cell transplantation (haplo‐ HSCT ) using post‐transplant cyclophosphamide (Cy) has shown high reproducibility and acceptable safety profile. Method This prospective cohort analysis allowed us to collect data on infections among 70 consecutive recipients haplo‐ affected by various hematologic malignancies. Results After median follow‐up 23 months, cumulative incidence viral was 70% (95% confidence...
This multicenter, open-label, phase II study evaluated the combination of bendamustine, gemcitabine, and vinorelbine (BeGEV) as induction therapy before autologous stem-cell transplantation (ASCT) in patients with relapsed or refractory Hodgkin lymphoma (HL).Patients HL who were to had after one previous chemotherapy line eligible. The primary end point was complete response (CR) rate four cycles therapy. Secondary points were: overall rate, mobilization activity, toxicity. Progression-free...
ADCT-402 (loncastuximab tesirine) is an antibody-drug conjugate comprising a CD19-targeting antibody and pyrrolobenzodiazepine dimers. A first-in-human study evaluated the safety preliminary clinical activity of loncastuximab tesirine in patients with B-cell non-Hodgkin lymphoma (NHL).A multicenter, phase I, dose-escalation dose-expansion enrolled ages ≥18 years relapsed/refractory (R/R) NHL. Patients received every 3 weeks at doses assigned by 3+3 design. Dose escalation was used to assess...
The coronavirus disease 2019 (COVID-19) pandemic, a viral illness caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2),1 has produced at time of this writing nearly 33 million cases infection, with over deaths in 235 countries,2 causing an unprecedented burden on healthcare systems and global socioeconomic crisis. As pandemic spreads, knowledge course, as well potential risk factors predictors severity is increasing daily, initial data from randomised controlled studies...
PURPOSE Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) have a poor prognosis. The phase I/II NP30179 study (ClinicalTrials.gov identifier: NCT03075696 ) evaluated glofitamab monotherapy in patients R/R B-cell lymphomas, obinutuzumab pretreatment (Gpt) to mitigate the risk of cytokine release syndrome (CRS) glofitamab. We present data for MCL. METHODS Eligible MCL (at least one previous therapy) received Gpt (1,000 or 2,000 mg) 7 days before first dose (single split over 2...
7008 Background: Glofitamab, a bispecific antibody with novel 2:1 (CD20:CD3) format, engages and redirects T cells to eliminate malignant B cells. In Phase I/II study (NCT03075696), fixed-duration glofitamab monotherapy showed high, durable complete responses (CR) manageable safety in patients (pts) heavily pretreated R/R MCL (Phillips et al. ASH 2022). We report updated efficacy data for pts MCL. Methods: Pts received obinutuzumab pretreatment (Gpt; 1000mg or 2000mg) 7 days before their...